NN-9487

Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.

Novo Nordisk introduces NovoCare Pharmacy, a direct-to-patient delivery service offering all Wegovy dose strengths at $499 per month for cash-paying and eligible commercially insured patients without coverage.

AbbVie makes its strategic entry into the obesity therapeutics market through a $350 million upfront licensing agreement with Danish biotech Gubra for their amylin analog GUB014295.

Novo Nordisk reported strong performance in Q4 2024, with Ozempic and Wegovy sales reaching DKK 53.7 billion, marking a 35.4% year-over-year growth despite market competition.

Novo Nordisk CEO Lars Jørgensen indicates readiness for Medicare price negotiations on GLP-1 drugs Wegovy, Ozempic, and Rybelsus, citing experience from previous insulin negotiations.